Digipath Announces Results for the Fiscal Year 2021
Digipath, Inc. (OTCQB: DIGP) reported its financial results for the fiscal year ending September 30, 2021. The company saw a 70.3% reduction in net loss to $686,503 compared to a loss of $2,309,490 the previous year. Total revenues decreased by 2.7% to $2,503,800, and gross margins were slightly down to 28.36%. Despite these figures, EBITDA improved significantly by $1,419,934. The company aims to expand through strategic acquisitions following a challenging year impacted by COVID.
- Net loss decreased by 70.3% to $686,503.
- EBITDA improved by $1,419,934 year-over-year.
- Reduced operating expenses from $2,988,217 to $1,487,613.
- Annual revenues decreased by $70,599 or 2.7%.
- Gross margins fell to 28.36%, down from 30.9%.
Economic impact of COVID continuing to subside as Company expands operations in California
LAS VEGAS, NV, Jan. 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Digipath, Inc. (OTCQB: DIGP) (“DIGP” or the “Company”), a service-oriented independent analytical testing laboratory, data analytics and technology firm focused on the cannabis and hemp markets, today announced results for the twelve month period ending September 30, 2021. Revenues and Gross Margins were reasonably consistent with the previous fiscal year, but the loss was substantially less at
Fiscal Year 2021 Company Highlights
· Company signs LOI to purchase Berkley lab, initiates multi-state operator strategy.
· Annual revenues decreased by
· Gross margins of
· EBITDA was (
· Net loss decreased to
· The full year filing can be found on our website: Digipath SEC Filings
Management Comment
“While this was undoubtably a rebuilding year as we managed COVID and its impact on our operations, our clients, and the market, the Company was able to reduce expenses through what we view as a necessary rebuilding phase. This now positions us to accelerate and expand both in our longstanding Las Vegas lab and through strategic acquisitions,” said Todd Denkin, Founder and President at Digipath.
“In fact, we believe the challenges we faced and overcame helped us craft a far more elegant and efficient business model that we can apply to existing laboratories we acquire in lucrative markets, allowing us to expand both the venerable, pioneering Digipath brand and revenue potential simultaneously,” added Denkin.
The table below shows the interim results and key metrics:
Years Ended September 30, | |||||
Increase/ | |||||
2021 | 2020 | Decrease | |||
Revenues (Thousands) | (70,599) | ||||
Cost of Sales | 1,788,635 | 1,778,564 | 10,071 | ||
Gross Profit Margins (%) | ( | ||||
Operating Expenses | 1,487,613 | 2,988,217 | 1,500,604 | ||
Operating Loss | (772,448) | (2,192,382) | 1,419,934 | ||
Net Loss | (686,503) | (2,309,490) | 1,622,987 | ||
EPS | ($.01) | ($.04) | $.03 |
About Digipath, Inc. (OTCQB: DIGP)
Digipath, Inc., is a service-oriented independent analytical testing and research and development laboratory and data analytics firm focused on the legal cannabis and hemp markets.
Digipath Labs provides pharmaceutical-grade analysis and testing to the cannabis industry to ensure producers, consumers and patients know exactly what is in the cannabis they ingest and to help maximize the quality of its client’s products through analysis, research, development, and standardization.
Information about Forward-Looking Statements
This press release contains “forward-looking statements” that include information relating to future events. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to: the Company's need for additional funding, the demand for the Company's products, governmental regulation of the cannabis industry, the Company's ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company's liquidity and financial strength to support its growth, and other risks that may be detailed from time-to-time in the Company's filings with the United States Securities and Exchange Commission. For a more detailed description of the risk factors and uncertainties affecting Digipath, please refer to the Company's recent Securities and Exchange Commission filings, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Investor Relations & Financial Media
Integrity Media
team@integritymedia.com
Toll Free: (888) 216-3595
FAQ
What were Digipath's financial results for FY 2021?
How did Digipath improve its EBITDA?